Spectral Diagnostics Inc. (OTCMKTS:EDTXF – Get Free Report) shares fell 4.9% on Thursday. The company traded as low as $0.7770 and last traded at $0.7770. Approximately 190 shares traded hands during trading, a decline of 98% from the average daily volume of 10,489 shares. The stock had previously closed at $0.8170.
Spectral Diagnostics Stock Performance
The company has a market cap of $228.94 million, a P/E ratio of -7.77 and a beta of 0.14. The firm’s fifty day moving average is $0.87 and its two-hundred day moving average is $0.95.
Spectral Diagnostics Company Profile
Spectral Diagnostics Inc, now known as Spectral Medical Inc, is a Canadian medical-device and biotechnology company focused on the diagnosis and treatment of sepsis and other conditions associated with systemic inflammation. The company’s work centers on identifying endotoxemia, a condition in which bacterial endotoxins enter the bloodstream and contribute to severe immune responses.
Spectral’s principal diagnostic product is the Endotoxin Activity Assay, or EAA, a blood test designed to measure a patient’s endotoxin activity and help clinicians assess the risk of developing severe sepsis.
Further Reading
- Five stocks we like better than Spectral Diagnostics
- Is Texas Instruments Setting Up for Its Next Big Breakout?
- Pegasystems’ Q3 Miss Exposed the Problem Standing Between AI and Cash Flow
- Lam Research’s Earnings Beat Wasn’t the Real Story—Its 2027 Outlook Was
- Tesla’s Flying-Car Hype Hits an Earnings Reality Check
Receive News & Ratings for Spectral Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spectral Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
